V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215604 | 20081686 | 1.76 | 66 | Curative (C) | null | 2018-05-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | N | FLUOROURACIL + MITOMYCIN + RT | 101054888 |
| 20215605 | 20081687 | 1.7 | 59.2 | Palliative (P) | 2018-10-15 | 2018-12-15 | HCX | 02 | N | IMATINIB | 100775031 |
| 20215606 | 20081688 | 1.7 | 88.8 | Curative (C) | 2016-05-16 | 2016-05-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101215236 |
| 20215608 | 20081690 | 1.68 | 107.2 | null | 2017-03-16 | 2017-03-23 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101485126 |
| 20215609 | 20081691 | 1.62 | 82.9 | Palliative (P) | 2017-07-15 | 2017-07-19 | GO2 TRIAL | Y | N | TRIAL | 101630740 |
| 20215611 | 20081693 | 1.59 | 59 | Palliative (P) | 2019-04-30 | 2019-05-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101191415 |
| 20215612 | 20081694 | 1.65 | 65 | null | 2016-09-18 | 2016-09-23 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100671339 |
| 20215613 | 20081695 | 1.56 | 77.2 | null | 2018-07-17 | 2018-08-06 | LANREOTIDE | N | null | LANREOTIDE | 101739583 |
| 20215614 | 20081696 | null | 0 | Palliative (P) | 2018-11-16 | 2018-12-22 | LANREOTIDE | 2 | N | LANREOTIDE | 100174704 |
| 20215615 | 20081697 | 1.43 | 59 | 03 | 2022-01-23 | 2022-02-21 | LANREOTIDE | 02 | N | LANREOTIDE | 101601419 |
| 20215617 | 20081698 | 1.72 | 65.4 | 03 | 2016-07-25 | 2016-07-26 | LANREOTIDE | 02 | N | LANREOTIDE | 100982701 |
| 20215618 | 20081699 | 1.75 | 78 | Curative (C) | 2016-10-03 | 2017-01-31 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101125870 |
| 20215619 | 20081700 | 0 | 80 | Neo-adjuvant (N) | 2020-01-03 | 2020-01-05 | Imatinib 400mg | 02 | N | IMATINIB | 100293204 |
| 20215620 | 20081701 | null | 65 | Curative (C) | 2017-10-03 | 2017-10-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100499947 |
| 20215621 | 20081702 | 1.75 | 90.1 | 03 | 2018-06-11 | 2018-06-12 | Imatinib 400mg | 02 | N | IMATINIB | 101783152 |
| 20215622 | 20081703 | null | null | null | 2017-08-31 | 2017-09-07 | LANREOTIDE | 02 | null | LANREOTIDE | 101459896 |
| 20215623 | 20081704 | null | 86.5 | Palliative (P) | 2018-10-04 | 2018-10-11 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100882737 |
| 20215625 | 20081705 | 1.76 | 66.8 | Palliative (P) | 2016-04-21 | 2016-04-21 | Trial Unspecified | Y | N | TRIAL | 101376578 |
| 20215626 | 20081706 | 1.61 | 83 | null | 2019-08-02 | 2019-08-22 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101722310 |
| 20215627 | 20081707 | 1.55 | 72.8 | Palliative (P) | 2020-01-12 | 2020-01-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100779304 |
| 20215628 | 20081708 | 0 | 0 | null | 2020-01-18 | 2020-02-22 | IMATINIB | 02 | null | IMATINIB | 100330937 |
| 20215629 | 20081709 | null | 81.9 | Palliative (P) | 2019-02-20 | 2019-02-20 | Trial Unspecified | 01 | N | TRIAL | 100962196 |
| 20215630 | 20081710 | 1.78 | 73 | Palliative (P) | 2018-07-05 | 2018-07-05 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100242920 |
| 20215631 | 20081711 | 1.65 | 61.3 | Palliative (P) | 2019-12-20 | 2019-12-21 | IMATINIB | 02 | N | IMATINIB | 100621962 |
| 20215632 | 20081712 | 1.75 | 96.5 | 02 | 2018-03-08 | 2018-03-22 | LANREOTIDE | 02 | N | LANREOTIDE | 100812793 |
| 20215633 | 20081713 | 1.72 | 82.9 | Palliative (P) | 2017-09-17 | 2017-09-28 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100805043 |
| 20215634 | 20081714 | 1.7 | 95.7 | Neo-adjuvant (N) | 2016-07-26 | 2016-08-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100782162 |
| 20215636 | 20081715 | 1.58 | 103.7 | Palliative (P) | 2017-02-19 | 2017-03-01 | Trial Unspecified | 01 | N | TRIAL | 101667911 |
| 20215637 | 20081716 | 1.54 | 63.2 | null | 2017-03-10 | 2017-03-23 | IMATINIB | 02 | null | IMATINIB | 100954864 |
| 20215638 | 20081717 | 1.7 | 87 | Palliative (P) | 2019-12-21 | 2019-12-29 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100759091 |
| 20215639 | 20081718 | 1.82 | 81 | Palliative (P) | 2018-06-01 | 2018-06-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101435601 |
| 20215640 | 20081719 | 1.54 | 54.9 | Palliative (P) | 2018-05-24 | 2018-06-09 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101635580 |
| 20215641 | 20081720 | 1.61 | 87.8 | null | 2019-05-02 | 2019-05-14 | HCX | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101284793 |
| 20215642 | 20081721 | 1.7 | 76 | Curative (C) | 2016-08-28 | 2016-08-31 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101129038 |
| 20215643 | 20081722 | 1.69 | 92 | null | 2017-03-25 | 2017-04-14 | Cape+Cisplatin+Trastuzumab Load | 02 | null | IMATINIB | 100674154 |
| 20215644 | 20081723 | 0 | 62.7 | Adjuvant (A) | 2017-08-15 | 2017-08-15 | IMATINIB | 02 | N | IMATINIB | 101405692 |
| 20215645 | 20081724 | 1.73 | 81.5 | Palliative (P) | 2017-10-03 | 2017-10-17 | Cetuximab + FLUOROURACIL + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100394192 |
| 20215646 | 20081725 | null | null | null | null | 2017-12-22 | null | null | null | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 100150976 |
| 20215648 | 20081727 | 1.56 | 81.8 | Palliative (P) | 2019-02-21 | 2019-03-15 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101541452 |
| 20215649 | 20081728 | 1.58 | 57.3 | Palliative (P) | 2018-01-29 | 2018-01-30 | LENVATINIB | 02 | N | LENVATINIB | 101392341 |
| 20215651 | 20081729 | 1.72 | 51.6 | Neo-adjuvant (N) | 2019-10-18 | 2019-10-18 | null | null | null | CETUXIMAB + IRINOTECAN + MDG | 101016631 |
| 20215652 | 20081730 | 1.55 | 73 | Palliative (P) | 2016-06-22 | 2016-07-16 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 02 | N | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100014194 |
| 20215655 | 20081733 | null | 45.8 | Curative (C) | null | 2018-02-09 | null | null | Y | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100459339 |
| 20215657 | 20081734 | 1.76 | 63.6 | Curative (C) | 2019-12-05 | 2019-12-12 | null | null | N | CETUXIMAB + IRINOTECAN + MDG | 101204443 |
| 20215659 | 20081735 | null | null | null | 2018-06-14 | 2018-06-20 | null | null | null | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100820050 |
| 20215662 | 20081736 | 1.58 | 70 | Adjuvant (A) | 2018-07-28 | 2018-08-08 | Cetuximab + FOLFIRI cycle1 | N | N | CETUXIMAB + IRINOTECAN + MDG | 100597449 |
| 20215663 | 20081737 | null | null | null | null | 2018-01-26 | null | null | null | CAPECITABINE + MITOMYCIN + RT | 100108496 |
| 20215665 | 20081739 | 1.59 | 73.2 | Palliative (P) | null | 2017-04-08 | null | null | Y | CISPLATIN + ETOPOSIDE | 101029366 |
| 20215666 | 20081740 | null | 81 | Neo-adjuvant (N) | null | 2019-03-01 | null | null | N | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 101142360 |
| 20215667 | 20081741 | 1.67 | 79 | Curative (C) | null | 2019-08-07 | null | null | Y | CAPECITABINE + MITOMYCIN + RT | 100946863 |